Korean Diabetes J.  2009 Oct;33(5):421-431. 10.4093/kdj.2009.33.5.421.

Leptin is Negatively Associated with Femoral Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes Mellitus

• Jeon JH
• Choi YK
• Seo HA
• Lee JE
• Jeong JY
• Moon SS
• Lee JY
• Kim JG
• Kim BW
• Lee IK

• KMID: 2231149
• DOI: http://doi.org/10.4093/kdj.2009.33.5.421

Abstract

BACKGROUND
Serum leptin level and bone mineral density (BMD) are widely assumed to be positively associated with body fat mass. Numerous attempts have been made to document the relationship between leptin and BMD, but the results are inconsistent, especially in diabetic patients.
METHODS
A total of 60 Korean postmenopausal women with type 2 diabetes mellitus were included in the present study. The BMDs of lumbar spines (L1 to L4) and proximal femurs (trochanter, neck, and total) were measured by dual-energy X-ray absorptiometry (DXA), and biochemical markers including leptin, HbA1c, C-peptide and urine albumin-creatinine ratio (ACR) were measured for each patient.
RESULTS
Negative associations between leptin and BMD of femoral neck, trochanter, and total femur in postmenopausal women with type 2 diabetes mellitus were documented in a model adjusted for age, body fat mass, and fasting insulin level (r = -0.308, P = 0.020 and r = - 0.303, P = 0.025 and r = - 0.290, P = 0.032 respectively). Multiple linear regression analysis was performed revealing negative associations between leptin and BMD of the femoral neck (beta = -0.369), trochanter (beta = -0.324), and total femur (beta = -0.317).
CONCLUSION
The results of the present study suggest a negative relationship between leptin and femoral BMD. In addition, leptin may have a negative effect on BMD in postmenopausal women with type 2 diabetes mellitus.

Keyword

Bone density; Leptin; Type 2 diabetes mellitus

MeSH Terms

Absorptiometry, Photon
Adipose Tissue
Biomarkers
Bone Density
C-Peptide
Diabetes Mellitus, Type 2
Fasting
Female
Femur
Femur Neck
Humans
Insulin
Leptin
Linear Models
Neck
Spine
C-Peptide
Insulin
Leptin

Figure

• 

  Fig. 1 Relationship between natural logarithm transformed serum leptin level and body fat mass (circle and dashed line) and body mass index (diamond and solid line).

• 

  Fig. 2 Relationship between natural logarithm transformed serum leptin level and fasting C-peptide level (circle and dashed line) and fasting insulin level (diamond and solid line).

• 

  Fig. 3 Relationship between BMD at various sites (L1, femur neck, trochanter and total) and body fat mass. Correlation coefficients and P values are shown in table 2.

• 

  Fig. 4 Relationship between BMD at various regions (L1, femur neck, trochanter and total) and natural logarithm transformed leptin. Correlation coefficients and P values are shown in table 2.

Reference

1. Reid IR, Ames R, Evans MC. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab. 1992. 75:45–51.

2. Frumar AM, Meldrum DR, Geola F, Shamonki IM, Tataryn IV, Deftos LJ, Judd HL. Relationship of fasting urinary calcium to circulating estrogen and body weight in postmenopausal women. J Clin Endocrinol Metab. 1980. 50:70–75.

3. Johnston CC Jr, Hui SL, Longcope C. Bone mass and sex steroid concentrations in postmenopausal Caucasian diabetics. Metabolism. 1985. 34:544–550.

4. Reid IR, Evans MC, Cooper GJ, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol. 1993. 265:655–659.

5. Rubin CT, Lanyon LE. Regulation of bone mass by mechanical strain magnitude. Calcif Tissue Int. 1985. 37:411–417.

6. Cock TA, Auwerx J. Leptin: cutting the fat off the bone. Lancet. 2003. 362:1572–1574.

7. Zhang Y, Proenca R, Maffei M, Barone M, Lori L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994. 372:425–432.

8. Couce ME, Burguera B, Parisi JE, Jensen MD, Lloyd RV. Localization of leptin receptor in the human brain. Neuroendocrinology. 1997. 66:145–150.

9. Ostlund RE Jr, Yang JW, Klein S, Gingerich R. Relation between plasma leptin concentration and body fat, gender, diet, age and metabolic covariates. J Clin Endocrinol Metab. 1996. 81:3909–3913.

10. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1998. 140:1630–1638.

11. Liu C, Grossman A, Bain S, Strachan M, Puerner D, Bailey C, Humes J, Lenox J, Yamamoto G, Sprugel K. Leptin stimulates cortical bone formation in obese (ob/ob) mice. J Bone Miner Res. 1997. 12:suppl 1. S11.

12. Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, Gough TU, Collier GU, Nicholson GU. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002. 17:200–209.

13. Steppan C, Crawford T, Chidsey-Frink K, Ke H, Swick A. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept. 2000. 92:73–78.

14. Ducy P, Amling M, Takeda S, Priemel M, Schilling A, Beil F, Shen J, Vinson C, Rueger J, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell. 2000. 100:197–207.

15. Karsenty G. Leptin controls bone formation through a hypothalamic relay. Recent Prog Horm Res. 2001. 56:401–415.

16. Takeda S, Elefteriou F, Levasseur R, Liu X, ZHAO L, Parker KL, Rmstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002. 111:305–317.

17. Ozata M, Ozdemir I, Licinio J. Human leptin deficiency caused by a missense mutation: Multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab. 1999. 84:3686–3695.

18. Goulding A, Taylor RW. Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int. 1998. 63:456–458.

19. Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, Ozuru R, Sugishita T, Chihara K. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf). 2001. 55:341–347.

20. Sato M, Takeda N, Sarui H, Takami R, Takami K, Hayashi M, Sasaki A, Kawachi S, Yoshino K, Yasuda K. Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men. J Clin Endocrinol Metab. 2001. 86:5273–5276.

21. Ormarsdottir S, Ljunggren O, Mallmin H, Olofsson H, Blum WF, Loof L. Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. J Gastroenterol Hepatol. 2001. 16:1409–1414.

22. Hofbauer L, Brueck C, Singh S, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007. 22:1317–1328.

23. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab. 2003. 21:166–171.

24. Kassem HS, Arabi A, Zantout MS, Azar ST. Negative effect of leptin on bone mass in type 1 diabetes. Acta Diabetol. 2008. 45:237–241.

25. American Diabetes Association. Standards of Medical Care in Diabetes 2008. Diabetes Care. 2008. 31:suppl 1. S12–S54.

26. Fukunaga Y, Minamikawa J, Inoue D, Koshiyama H. Does insulin use increase bone mineral density in patients with non-insulin-dependent diabetes mellitus? Arch Intern Med. 1997. 157:2668–2669.

27. Weinstock RS, Goland RS, Shane E, Clemens TL, Lindsay R, Bilezikian JP. Bone mineral density in women with type II diabetes mellitus. J Bone Miner Res. 1989. 4:97–101.

28. Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005. 289:E735–E745.

29. Einhorn TA, Boskey AL, Gundberg CM, Vigorita VJ, Devlin VJ, Beyer MM. The mineral and mechanical properties of bone in chronic experimental diabetes. J Orthop Res. 1988. 6:317–323.

30. Campos Pastor MM, López-Ibarra PJ, Escobar-Jiménez F, Serrano Pardo MD, García-Cervigón AG. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int. 2000. 11:455–459.

31. Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005. 16:1506–1512.

32. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005. 16:1713–1720.

33. Thommesen L, Stunes AK, Monjo M, Grøsvik K, Tamburstuen MV, Kjøbli E, Lyngstadaas SP, Reseland JE, Syversen U. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem. 2006. 99:824–834.

34. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol. 2009. 160:265–273.

35. Cornish J, Callon KE, Cooper GJ, Reid IR. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun. 1995. 207:133–139.

36. Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G. UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab. 1997. 82:654–657.

37. Abou SR, Baba N, Torbay N, Dib L, Fuleihan GE. High plasma leptin is not associated with higher bone mineral density in insulin-resistant premenopausal obese women. J Clin Endocrinol Metab. 2005. 90:2588–2594.

38. Martin A, David V, Malaval L, Afage-Prous MH, Vico L, Thomas T. Opposite effects of leptin on bone metabolisms: a dose-dependent balance related to energy intake and IGF-I pathway. Endocrinology. 2007. 148:3419–3425.

39. Hamrick MW. Leptin, bone mass, and the thrifty phenotype. J Bone Miner Res. 2004. 19:1607–1611.

40. Scarpace PJ, Tümer N. Peripheral and hypothalamic leptin resistance with age-related obesity. Physiol Behav. 2001. 74:721–727.